Alectos Therapeutics is a leading company specializing in the discovery and preclinical development of small-molecule therapeutics for neurological diseases. With a primary focus on neurodegenerative conditions like Alzheimer's disease and Parkinson's disease, Alectos pioneers innovative strategies to block the underlying progression of these diseases. They have developed a pipeline of potential treatments to address the complex nature of neurological conditions.

One of their programs, the GBA2 program, aims to correct lysosomal dysfunction in Parkinson's disease, and it has recently been partnered with Biogen. Another program, the OGA program, focuses on preventing the accumulation and spread of toxic protein aggregates in the brain and has a partnership with Merck. Alectos has repatriated this program and is utilizing their expertise to further advance novel OGA inhibitors for Alzheimer's disease, frontotemporal dementia, and ischemic stroke.

As a company committed to the development of disease-modifying therapies for neurodegenerative diseases, Alectos welcomes partnership inquiries regarding their OGA program and their advanced preclinical development candidates. With their groundbreaking research and collaborations, Alectos Therapeutics strives to make a significant impact in the field of neuroscience